<DOC>
	<DOCNO>NCT02212574</DOCNO>
	<brief_summary>Participants enrol study receive standard care chemotherapy Wnt positive medulloblastoma without radiation therapy weekly chemotherapy give radiation therapy .</brief_summary>
	<brief_title>Study Assessing Feasibility Surgery Chemotherapy-Only Children With Wnt Positive Medulloblastoma</brief_title>
	<detailed_description>There 9 cycle chemotherapy . There two different kind cycle give . They refer A B . Cycle A last 6 week Cycle B last 4 week . B cycle give completion two A cycle . Below detail drug schedule A B cycle . Cycle A ( This cycle last 42 day ) - Lomustine ( CCNU ) give mouth Day 1 . - Vincristine give directly vein ( IV ) one minute use minibag several minute institution Days 1 , 8 , 15 . - Cisplatin give directly vein 8 hour Day 1 Cycle B ( This cycle last 28 day ) - Cyclophosphamide give vein 1 hour Days 1 2 . - MESNA , drug protect bladder effect cyclophosphamide , give 15 minute dose cyclophosphamide repeat 3 6 hour . - Vincristine give directly vein directly vein ( IV ) one minute use minibag several minute institution Days 1 8 . You may also get supportive care drug call myeloid growth factor ( filgrastim pegfilgrastim ) . This drug help blood count recover chemotherapy give .</detailed_description>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>Participants must classical histology posterior fossa medulloblastoma determine institutional neuropathological evaluation . Institutional beta catenin stain must demonstrate nuclear reactivity immunohistochemistry Sufficient pathologic material must available central analysis review Tumors deem Wnt positive , time central analysis , : Confirmation betacatenin nuclear reactivity immunohistochemistry . Monosomy 6 determine array CGH Absence MYCN MYC amplification ( determined FISH ) Absence largecell , anaplastic histology Absence residual disseminate disease define follow criterion : Minimal residual disease determine postoperative imaging preferably perform within 48 hour resection ( 28 day postsurgery ) , i.e . gross total resection residual disease &lt; 1.5cm2 postoperative imaging . No evidence metastatic disease brain , spine cerebral spinal fluid ( CSF ) . Assessments must include MRI image brain spine without contrast lumbar puncture CSF cytology Patients must radiation therapy chemotherapy medulloblastoma prior study enrollment Patients must Lansky performance status &gt; /=30 child &lt; /=10 year age Karnofsky performance status &gt; 30 child &gt; 10 year age . Participants must normal organ marrow function define : Hemoglobin great 10 g/dL ( transfuse ) . Hemoglobin &lt; 10 g/dL due operative blood loss permit . Absolute neutrophil count &gt; 1.0x109/L Platelets &gt; 100,000/uL ( nontransfused ) Total bilirubin &lt; 1.5 x upper limit normal SGOT ( AST ) SGPT ( ALT ) &lt; 2.5 x upper limit normal ( ULN ) age Creatinine clearance radioisotope GFR &gt; 70 ml/min/1.73m2 normal serum creatinine patient 's age gender All females childbearing age must negative pregnancy test enrol study . All patient childbearing age must practice effective method birth control whilst undergo chemotherapy study . No history allergic reaction attribute compound similar chemical biologic composition cisplatin , lomustine , vincristine cyclophosphamide .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Wnt</keyword>
	<keyword>Medulloblastoma</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>